Leerink Partners Reaffirms "Market Perform" Rating for aTyr Pharma (NASDAQ:ATYR)

aTyr Pharma (NASDAQ:ATYR - Get Free Report)'s stock had its "market perform" rating reissued by Leerink Partners in a research note issued to investors on Monday, MarketBeat.com reports.Several other research analysts have also commented on ATYR. Wall Street Zen lowered aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Wells Fargo & Company boosted their price objective on aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, June 20th. Cantor Fitzgerald cut aTyr Pharma from an "overweight" rating to a "neutral" rating in a report on Monday. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of aTyr Pharma in a report on Wednesday, June 4th. Finally, Jefferies Financial Group raised their target price on aTyr Pharma from $9.00 to $17.00 and gave the stock a "buy" rating in a research report on Friday, August 22nd. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $23.25.Check Out Our Latest Stock Analysis on aTyr PharmaaTyr Pharma Stock Up 12.3%NASDAQ:ATYR traded up $0.13 during trading hours on Monday, hitting $1.15. The stock had a trading volume of 25,653,677 shares, compared to its average volume of 3,689,492. The company has a market cap of $112.20 million, a PE ratio of -1.43 and a beta of 1.01. The business has a 50 day simple moving average of $5.28 and a two-hundred day simple moving average of $4.37. aTyr Pharma has a 1-year low of $1.00 and a 1-year high of $7.29. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04). Analysts predict that aTyr Pharma will post -0.91 EPS for the current year. Institutional Inflows and OutflowsInstitutional investors and hedge funds have recently bought and sold shares of the company. Group One Trading LLC acquired a new position in shares of aTyr Pharma during the 4th quarter worth about $26,000. California State Teachers Retirement System bought a new position in aTyr Pharma during the second quarter worth $28,000. Y Intercept Hong Kong Ltd bought a new position in aTyr Pharma during the first quarter worth $38,000. Two Sigma Advisers LP acquired a new position in aTyr Pharma during the 4th quarter valued at $44,000. Finally, Ameritas Investment Partners Inc. bought a new stake in aTyr Pharma in the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 61.72% of the company's stock. About aTyr Pharma (Get Free Report)aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Featured ArticlesFive stocks we like better than aTyr PharmaHigh Dividend REITs: Are They an Ideal Way to Diversify?3 Under-the-Radar Stocks Set to Benefit From Oracle’s BoomBusiness Services Stocks InvestingLululemon’s Sell-Off Looks Overdone: A Contrarian Case3 Warren Buffett Stocks to Buy NowHow Bath & Body Works Is a Perfect Example of a Value Stock Should You Invest $1,000 in aTyr Pharma Right Now?Before you consider aTyr Pharma, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and aTyr Pharma wasn't on the list.While aTyr Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here